Unfit patients even have the alternative of venetoclax plus obinutuzumab (VO) as frontline therapy. This relies over a phase III demo that in contrast VO with ClbO in aged/unfit clients.113 VO was outstanding in terms of reaction rate and progression-totally free survival, and experienced a comparable security profile. In this https://omarj319gpx7.blogmazing.com/profile